Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SRP-9005 in LGMD2C (COMPASS)
NCT06952686Phase 3Withdrawn
- Sponsor
- Sarepta Therapeutics
- Start
- Jun 2025
- Primary completion
- Nov 2030
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 1
01
Overview
A Phase 3 trial of SRP-9005 in limb-girdle muscular dystrophy type 2C (LGMD2C), sponsored by Sarepta Therapeutics. Planned start Jun 2025; status: withdrawn.
02
Drugs
SRP-9005
03
Conditions
limb-girdle muscular dystrophy type 2C (LGMD2C)
Beyond the preview
Go deeper on NCT06952686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06952686.